London, UK. 26 July 2011. A new report by visiongain, a London-based business information company, predicts that world drug revenues for treating inflammatory bowel diseases will reach $6.9bn in 2015. The IBD drug market generated revenues of $5bn in 2010, according to Inflammatory Bowel Diseases: World Drug Market 2011-2021, published in July 2011.
Inflammatory bowel diseases (IBD) are autoimmune disorders in which parts of the intestinal tract experience severe and chronic inflammation. The main forms are Crohn's disease and ulcerative colitis. Inflammatory bowel diseases damage the bowel irreversibly, causing serious discomfort and difficulties for patients. Surgery and drugs have improved patients' lives.
Diya Lahiri, pharmaceutical industry analyst, said: "The world IBD treatments market will benefit from the entry of new technologies, products and companies this decade. There are prominent needs in the IBD treatment market, the most important being the development of drugs that are disease modifying rather than only symptom managing. R&D efforts will help develop novel treatments that will not only benefit patients but also help researchers better understand IBD."
Visiongain forecasts that the IBD drug market will expand steadily to 2021. The future of the market appears promising, with increasing demand for IBD treatments. There is a strong R&D pipeline for treating inflammatory bowel diseases. The prospect of new, more-effective drugs, including biologics and intestinal anti-inflammatory agents (IAIs), will help this market to grow. This new study adds to visiongain's wide range of analytical reports in healthcare and other industry
For more information about this report please visit http://www.visiongain.com/Report/650/Inflammatory-Bowel-Diseases-World-Drug-Market-2011-2021
For an exec summary please contact:
Sara Peerun
Email: Sara.peerun@visiongainglobal.com
Tel: +44 0207 336 6100
ENDS
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100
About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Pharmaceutical, Telecoms, Energy, Defence and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.